9 May 2023 - Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which Rinvoq delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo.

AbbVie today announced that Health Canada has approved Rinvoq (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response to a biologic disease modifying anti-rheumatic drug or when use of those therapies is inadvisable.

Read AbbVie press release